Neuronostics: Pioneering Epilepsy Diagnosis Technology Raises £2.1M Funding
The multi-award-winning University of Exeter spin-out company, Neuronostics, has raised more than £2 million funding to develop its pioneering epilepsy diagnosis technology. The company has received £2.1M in funding through a successful round of seed funding, led by the Ascension Life Fund. The new funding, along with backing from a syndicate of additional investors including QantX, the Cornwall and Isles of Scilly Investment Fund managed by The FSE Group and Empirical Ventures, will allow Neuronostics to accelerate its route to market in the UK and Middle East, while also begin seeking regulatory approval from the FDA for the US market. Chris Wheatcroft, Investment Director at the Ascension Life Fund, said “We are delighted to have invested in Neuronostics, whose software as a medical device could revolutionise how neurological conditions are diagnosed and treated.”
Neuronostics was co-founded by Professor Terry and Dr Wessel Woldman in 2018. Their research is focused on the development and application of mathematical and computational methodologies for understanding the dynamics of biomedical systems, with particular interests in the transitions between healthy and unhealthy states in the human brain. As part of their work, the company are developing a pioneering patented biomarker of epilepsy, called BioEP. This digital biomarker reveals features from routinely collected clinical recordings that are currently hidden from clinical practice. These features indicate how likely a person is to have epilepsy, which supports a neurologist in determining the most appropriate next steps and also enhances the diagnostic capabilities of EEGs.
Traditionally, EEGs are used in clinical settings to visually identify abnormalities indicative of epilepsy, such as interictal spikes or discharges.
However, these features are absent in approximately 70% of EEGs, making the diagnosis of epilepsy challenging and typically delayed. BioEP™ enhances EEG analysis by detecting epilepsy-associated features in routine recordings, even when traditional epileptiform rhythms are absent. This approach can speed up diagnosis meaning patients receive more effective treatment sooner and relieves downstream pressures by reducing costly further testing. Neuronostics have now received a further £350K grant from Innovate UK through, its Investor Partnerships programme, to develop the BioEP platform.
They've invested in Neuronostics
Get to know these Healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Ascension Ventures( ) Ascension is a leading UK venture capital firm focused on empowering tech innova... London  | ||||
 QantX( ) | ||||
 Empirical Ventures( ) Empirical is a specialist VC and venture builder based in Europe, focusing on ea... Bristol | ||||
 | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK